Angelman Syndrome: How late is too late for treatment?

Experiments on mice suggest that an approach called antisense oligonucleotide therapy may be able to treat some symptoms of Angelman syndrome, including problems with epilepsy and sleep.
  • Download
  • Cite
  • CommentOpen annotations (there are currently 0 annotations on this page).
  1. Lawrence T Reiter  Is a corresponding author
  1. Department of Neurology, Department of Pediatrics, Department of Anatomy and Neurobiology, College of Medicine, University of Tennessee Health Science Center, United States

An approach called antisense oligonucleotide (ASO) therapy has ushered in a new age in genetic medicine. ASO therapy works by introducing a short strand of RNA that binds to specific messenger RNA (mRNA) molecules in the host, and thus prevents the mRNA from being translated. Clinical trials are currently under way to see if ASO therapy will work for various neurodevelopmental disorders, including Dravet syndrome (an epilepsy disorder), spinal muscular atrophy (a neuromuscular condition) and Batten’s disease (a devastating lysosomal storage disorder; Hill and Meisler, 2021).

Angelman syndrome is a neurodevelopmental disorder that is considered an ideal candidate for ASO therapy. Symptoms appear very early in childhood and include learning disabilities, abnormally happy demeanor, epilepsy, and difficulty controlling motor function, particularly while walking (Dagli et al., 1993). Children with Angelman syndrome also suffer from sleep problems. It has previously been shown, using cellular and animal models, that the regulation of a single gene, UBE3A, in the nervous system leads to the major features of Angelman syndrome (Kishino et al., 1997; Matsuura et al., 1997; Sutcliffe et al., 1997). UBE3A is found on chromosome 15, and most cases of Angelman syndrome are the result of a large deletion in the maternal copy of this chromosome. This means that most individuals have a working – but silent – paternal copy of UBE3A on chromosome 15. However, this copy is silenced by an antisense transcript which interferes with the expression of the paternal UBE3A.

Using ASO therapy to interfere with the antisense transcript – and thus allowing the intact copy of UBE3A to be expressed – is a promising approach for the treatment of Angelman syndrome. However, some scientists remain skeptical about the potential for ASO therapy to treat neurodevelopmental disorders, and several questions remain regarding how these treatments will work. For example, when does it become too late in human development to reactivate a missing gene in the nervous system? Are there neurogenetic diseases that can be rescued in adulthood? And, if so, what features of the disease can be treated with ASO therapies?

Extensive research has focused on answering these questions by reactivating the paternal copy UBE3A in a commonly used mouse model for Angelman syndrome. One goal of these studies has been to determine which symptoms can be reduced or eliminated. Another goal, which may be more challenging to achieve, is to establish when the gene should be reactivated during development in order to achieve the desired effect.

In 2018, researchers at the Erasmus Medical Center in Rotterdam published a set of behaviors that can be used to assess phenotypes for motor performance, repetitive behavior, anxiety, and seizure susceptibility using Ube3a maternal deficient mice (Sonzogni et al., 2018). These behaviors provide a framework to test the effectiveness of drugs (or ASOs) that reactivate the silent paternal copy of the gene. However, there are not many studies that dig deeper into the cognitive issues, sleep or epilepsy-related brain activity (as measured with EEG) that are known to be affected in this mouse model. Now, in eLife, Mingshan Xue and colleagues from Baylor College of Medicine and Ionis Pharmaceuticals – including Dongwon Lee, Wu Chen, Heet Naresh Kaku and Xinming Zhuo as first authors – report on the use of an ASO to rescue the characteristic EEG pattern and disordered sleep observed in a mouse model of Angelman syndrome (Lee et al., 2023).

First, Lee et al. designed a new Angelman syndrome mouse model that is less ‘leaky’ than the model used by other labs in previous studies – that is, a model where Ube3a expression from the maternal chromosome was more completely blocked. Then they injected the mice with an ASO against the Ube3a antisense transcript to see if the expression of the Ube3a protein could be rescued from the paternal chromosome. The results showed that, after injecting the mice with the ASO, the levels of Ube3a protein increased in multiple regions of the brain, including the cortex, the hippocampus and the hypothalamus, which controls sleep. Importantly, Ube3a expression was rescued in both juvenile and adult animals, which had previously been challenging.

Next, Lee et al. showed that the electrical activity in the brain of these mice is significantly rescued by injection of this ASO, in both juvenile and adult animals. They were also able to rescue the low level of rapid eye movement (REM) sleep observed in individuals with Angelman syndrome, with animals getting an almost normal amount of REM sleep six weeks after injection with the ASO.

The findings of Lee et al. illustrate that it may be possible to treat some aspects of Angelman syndrome after birth, and even into adulthood, using ASO therapeutics. This challenges the current view of what symptoms of Angelman syndrome are treatable, and at what age. While the delivery of ASOs to the brain is still a struggle, the latest results are encouraging for potential treatments for Angelman syndrome, and perhaps other neurodevelopmental disorders thought to be untreatable after birth.

References

  1. Website
    1. Dagli AI
    2. Mathews J
    3. Williams CA
    (1993) Angelman syndrome
    GeneReviews. Accessed February 2, 2023.

Article and author information

Author details

  1. Lawrence T Reiter

    Lawrence T Reiter is in the Department of Neurology, the Department of Pediatrics and the Department of Anatomy and Neurobiology, College of Medicine, University of Tennessee Health Science Center, Memphis, United States

    For correspondence
    lreiter@uthsc.edu
    Competing interests
    No competing interests declared
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4100-2630

Publication history

  1. Version of Record published:

Copyright

© 2023, Reiter

This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.

Download links

Further reading

    1. Medicine
    Feilin Cao, Zhaosheng Ma ... Shifen Huang
    Research Article

    Background:

    Approximately one-third of patients with HER2-positive breast cancer experienced recurrence within 10 years after receiving 1 year of adjuvant trastuzumab. The ExteNET study showed that 1 year of extended adjuvant neratinib after trastuzumab-based adjuvant therapy could reduce invasive disease-free survival (iDFS) events compared with placebo. This study investigated the efficacy and safety of pyrotinib, an irreversible pan-HER receptor tyrosine kinase inhibitor, after trastuzumab-based adjuvant therapy in patients with high-risk, HER2-positive early or locally advanced breast cancer.

    Methods:

    This multicenter phase II trial was conducted at 23 centers in China. After enrollment, patients received 1 year of extended adjuvant pyrotinib (400 mg/day), which should be initiated within 6 months after the completion of 1-year adjuvant therapy (trastuzumab alone or plus pertuzumab). The primary endpoint was 2-year iDFS rate.

    Results:

    Between January 2019 and February 2022, 141 eligible women were enrolled and treated. As of October 10, 2022, the median follow-up was 24 (interquartile range, 18.0–34.0) months. The 2-year iDFS rate was 94.59% (95% confidence interval [CI]: 88.97–97.38) in all patients, 94.90% (95% CI: 86.97–98.06) in patients who completed 1-year treatment, 90.32% (95% CI: 72.93–96.77) in patients who completed only 6-month treatment, 96.74% (95% CI: 87.57–99.18) in the hormone receptor (HR)-positive subgroup, 92.77% (95% CI: 83.48–96.93) in the HR-negative subgroup, 96.88% (95% CI: 79.82–99.55) in the lymph node-negative subgroup, 93.85% (95% CI: 86.81–97.20) in the lymph node-positive subgroup, 97.30% (95% CI: 82.32–99.61) in patients with adjuvant trastuzumab plus pertuzumab, and 93.48% (95% CI: 86.06–97.02) in patients with adjuvant trastuzumab. The most common adverse events were diarrhea (79.4%), fatigue (36.9%), lymphocyte count decreased (36.9%), nausea (33.3%), and hand-foot syndrome (33.3%).

    Conclusions:

    Extended adjuvant pyrotinib administrated after trastuzumab-based adjuvant therapy showed promising efficacy in patients with high-risk HER2-positive breast cancer. The follow-up is ongoing to determine the long-term benefit.

    Funding:

    No external funding was received for this work.

    Clinical trial number:

    ClinicalTrials.gov: NCT05880927

    1. Immunology and Inflammation
    2. Medicine
    Haiyi Fei, Xiaowen Lu ... Lingling Jiang
    Research Article

    Preeclampsia (PE), a major cause of maternal and perinatal mortality with highly heterogeneous causes and symptoms, is usually complicated by gestational diabetes mellitus (GDM). However, a comprehensive understanding of the immune microenvironment in the placenta of PE and the differences between PE and GDM is still lacking. In this study, cytometry by time of flight indicated that the frequencies of memory-like Th17 cells (CD45RACCR7+IL-17A+CD4+), memory-like CD8+ T cells (CD38+CXCR3CCR7+HeliosCD127CD8+) and pro-inflam Macs (CD206CD163CD38midCD107alowCD86midHLA-DRmidCD14+) were increased, while the frequencies of anti-inflam Macs (CD206+CD163CD86midCD33+HLA-DR+CD14+) and granulocyte myeloid-derived suppressor cells (gMDSCs, CD11b+CD15hiHLA-DRlow) were decreased in the placenta of PE compared with that of normal pregnancy (NP), but not in that of GDM or GDM&PE. The pro-inflam Macs were positively correlated with memory-like Th17 cells and memory-like CD8+ T cells but negatively correlated with gMDSCs. Single-cell RNA sequencing revealed that transferring the F4/80+CD206 pro-inflam Macs with a Folr2+Ccl7+Ccl8+C1qa+C1qb+C1qc+ phenotype from the uterus of PE mice to normal pregnant mice induced the production of memory-like IL-17a+Rora+Il1r1+TNF+Cxcr6+S100a4+CD44+ Th17 cells via IGF1–IGF1R, which contributed to the development and recurrence of PE. Pro-inflam Macs also induced the production of memory-like CD8+ T cells but inhibited the production of Ly6g+S100a8+S100a9+Retnlg+Wfdc21+ gMDSCs at the maternal–fetal interface, leading to PE-like symptoms in mice. In conclusion, this study revealed the PE-specific immune cell network, which was regulated by pro-inflam Macs, providing new ideas about the pathogenesis of PE.